New drug iptacopan tested in Real-Life PNH patients
NCT ID NCT07229235
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how well the drug iptacopan works for people with paroxysmal nocturnal hemoglobinuria (PNH) in everyday medical practice. Researchers will track 50 Italian patients for 12 months to see if their anemia improves and if they need fewer blood transfusions. The goal is to understand the drug's real-world benefits and safety outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iptacopan
What this could lead to
If successful, this study could confirm that iptacopan works well in everyday medical practice for PNH patients, potentially improving anemia and reducing the need for blood transfusions.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection or concurrent treatments. It is also small (50 patients) and limited to Italy, so findings may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGAlessandria, AL, 15121, Italy
-
Novartis Investigative Site
RECRUITINGAvellino, AV, 83100, Italy
-
Novartis Investigative Site
RECRUITINGBrescia, BS, 25123, Italy
-
Novartis Investigative Site
RECRUITINGFlorence, FI, 50134, Italy
-
Novartis Investigative Site
RECRUITINGGenova, GE, 16132, Italy
-
Novartis Investigative Site
RECRUITINGMilan, MI, 20122, Italy
-
Novartis Investigative Site
RECRUITINGMilan, MI, 20132, Italy
-
Novartis Investigative Site
RECRUITINGPalermo, PA, 90146, Italy
-
Novartis Investigative Site
RECRUITINGRoma, RM, 00161, Italy
-
Novartis Investigative Site
RECRUITINGRoma, RM, 00168, Italy
-
Novartis Investigative Site
RECRUITINGTorino, TO, 10126, Italy
-
Novartis Investigative Site
RECRUITINGBassano del Grappa, VI, 36061, Italy